CD38 and Miyoshi myopathy: We developed an efficient CRISPR gene editing platform to disrupt the expression of CD38, which reduced DARA-mediated NK cell fratricide, improved NK cell persistence in the presence of DARA, and augmented DARA-driven ADCC against CD38-expressing MM cell lines.